The role of amphiregulin in mediating radiation cystitis in cancer survivors

双调蛋白在介导癌症幸存者放射性膀胱炎中的作用

基本信息

项目摘要

ABSTRACT Cancer survivors are a growing population in the United States, though many of them pay a heavy price for their survivorship status due to long-term side effects from cancer therapies. Radiation cystitis (RC) results from radiation therapy for pelvic cancers. RC is a debilitating and progressive bladder condition with no effective therapy that may be life-threatening. Thus, the treatment that killed the cancer, may ultimately kill the cancer survivor as well. Research in cancer survivorship is highly significant and represent a great unmet need. This grant proposal is greatly innovative and results from our studies may lead to new diagnosis and treatment for radiation cystitis. The PI, Bernadette Zwaans, PhD, completed a successful and productive NIDDK K01 training award. The KO1 was focused on a systematic research on better understanding of radiation cystitis using SARRP at the capable and resourceful environment at Beaumont Research Institute. We developed an RC preclinical model that closely mimics the human condition. In this model, we identified that RC is a biphasic condition, characterized by urothelial damage in the weeks after radiation therapy (=acute RC), and by chronic fibrosis, vascular damage, and loss of detrusor muscle in months to years after radiation therapy (= chronic RC). We have identified Amphiregulin (AREG) to be significantly elevated after radiation therapy, and to continue to grow in abundance over time. AREG is a member of the epidermal growth factor family that binds the EGF receptor. It has been implicated in many processes including tissue regeneration, cancer, tissue fibrosis, and cellular senescence. AREG is present throughout the body but is most prominently expressed in the bladder urothelium. We hypothesize that AREG mediates radiation-induced bladder fibrosis and can serve as a potential therapeutic target. We further hypothesize that AREG can serve as a predictive urine biomarker to identify patients that are at risk for developing chronic RC. Our hypothesis will be tested through three specific aims: 1. Determine the expression pattern of AREG and its importance in maintaining urothelial integrity in normal and irradiated bladder; 2. Determine the role of AREG in mediating radiation-induced fibrosis; 3. Assess AREG as a predictive biomarker for RC. Given our experience with RC preclinical models our team is well-suited to successfully complete these aims. This study is investigating the first potential therapeutic target for RC and its use as a predictive urine biomarker. The outcomes of our studies can significantly improve the quality of life of many cancer survivors suffering from severe bladder complications due to radiation therapy. Thus, this study falls within the mission statement of the NIDDK to improve health and quality of life of cancer survivors.
抽象的 癌症幸存者在美国的人口增长,尽管其中许多人付出了沉重的代价 由于癌症疗法的长期副作用,他们的生存状况。辐射膀胱炎(RC)结果 从骨盆癌的放射治疗。 RC是一种令人衰弱和渐进的膀胱状态,没有 有效的疗法可能会威胁生命。因此,杀死癌症的治疗方法可能最终杀死 癌症幸存者也是如此。癌症生存研究的研究非常重要,代表了很大的 未满足的需求。该赠款提案具有很大的创新性,我们的研究结果可能会导致新的 诊断和治疗辐射膀胱炎。 PI,Bernadette Zwaans博士获得了一项成功且富有成效的NIDDK K01培训奖。这 KO1专注于对使用SARRP更好地理解辐射膀胱炎的系统研究 Beaumont研究所的能力且足智多谋的环境。我们开发了RC 紧密模仿人类状况的临床前模型。在此模型中,我们确定RC是双相 病情,以尿路疗法后的几周(=急性RC)和 放射治疗后的几个月至数年,慢性纤维化,血管损伤和迫切肌肉的丧失(= 慢性RC)。我们已经确定放射治疗后的两次两极蛋白(AREG)显着升高 随着时间的流逝,继续增长。 AREG是表皮生长因子家族的成员 结合EGF受体。它与许多过程有关,包括组织再生, 癌症,组织纤维化和细胞衰老。 AREG在整个身体中都存在,但最多 在膀胱尿铺上明显表达。我们假设AREG介导了辐射诱导的 膀胱纤维化,可以作为潜在的治疗靶点。我们进一步假设AREG 可以用作预测性尿液生物标志物,以识别有慢性慢性风险的患者 RC。 我们的假设将通过三个特定目的进行检验:1。确定AREG的表达模式 以及它在维持正常和辐照膀胱中尿路上皮完整性方面的重要性; 2。确定角色 AREG在介导辐射诱导的纤维化中; 3。评估AREG作为RC的预测生物标志物。给出 我们在RC临床前模型的经验非常适合成功完成这些目标。 这项研究正在研究RC的第一个潜在治疗靶点及其用作预测性尿液 生物标志物。我们研究的结果可以显着改善许多癌症的生活质量 由于放射治疗而患有严重膀胱并发症的幸存者。因此,这项研究属于 NIDDK的任务陈述,以改善癌症幸存者的健康和生活质量。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Identification of Molecular Mechanisms in Radiation Cystitis: Insights from RNA Sequencing.
放射性膀胱炎分子机制的鉴定:RNA 测序的见解。
  • DOI:
    10.3390/ijms25052632
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Mota,Sabrina;Ward,ElijahP;Bartolone,SarahN;Chancellor,MichaelB;Zwaans,BernadetteMM
  • 通讯作者:
    Zwaans,BernadetteMM
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bernadette Margaretha Maria Zwaans其他文献

Bernadette Margaretha Maria Zwaans的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bernadette Margaretha Maria Zwaans', 18)}}的其他基金

Cancer Survivorship Research and Training in Radiation Cystitis
放射性膀胱炎的癌症生存研究和培训
  • 批准号:
    9768473
  • 财政年份:
    2018
  • 资助金额:
    $ 43.92万
  • 项目类别:
Cancer Survivorship Research and Training in Radiation Cystitis
放射性膀胱炎的癌症生存研究和培训
  • 批准号:
    10226404
  • 财政年份:
    2018
  • 资助金额:
    $ 43.92万
  • 项目类别:

相似国自然基金

用于急性出血控制的硅酸钙复合海绵的构建及其促凝血性能和机制研究
  • 批准号:
    32301097
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
AF9通过ARRB2-MRGPRB2介导肠固有肥大细胞活化促进重症急性胰腺炎发生MOF的研究
  • 批准号:
    82300739
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
代谢工程化MSC胞外囊泡靶向调控巨噬细胞线粒体动力学改善急性肾损伤的作用及机制研究
  • 批准号:
    32371426
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
DUSP2介导自噬调控气管上皮细胞炎症在急性肺损伤中的机制研究
  • 批准号:
    82360379
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
超声射频信号神经回路策略模型定量肌肉脂肪化评估慢加急性肝衰竭预后
  • 批准号:
    82302221
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Predicting the Absence of Serious Bacterial Infection in the PICU
预测 PICU 中不存在严重细菌感染
  • 批准号:
    10806039
  • 财政年份:
    2023
  • 资助金额:
    $ 43.92万
  • 项目类别:
Acute Kidney Injury in Children with Chronic Kidney Disease
慢性肾病儿童的急性肾损伤
  • 批准号:
    10638267
  • 财政年份:
    2023
  • 资助金额:
    $ 43.92万
  • 项目类别:
Comprehensive, Real Time Monitoring of the Accumulation and Clearance of Small Molecules in Kidney Disease
全面、实时监测肾脏疾病中小分子的积累和清除
  • 批准号:
    10863011
  • 财政年份:
    2023
  • 资助金额:
    $ 43.92万
  • 项目类别:
Pre-Clinical Core
临床前核心
  • 批准号:
    10746570
  • 财政年份:
    2023
  • 资助金额:
    $ 43.92万
  • 项目类别:
Cellular and Molecular Response to Gentamicin-Induced Injury in Underdeveloped Kidneys
发育不全的肾脏对庆大霉素引起的损伤的细胞和分子反应
  • 批准号:
    10591824
  • 财政年份:
    2023
  • 资助金额:
    $ 43.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了